A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

Status:
NOT_YET_RECRUITING

Trial end date:
2029-08-04

Target enrollment:

Participant gender:

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

PHASE3

Bristol-Myers Squibb

trospium chloride
xanomeline